Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
Titel:
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
Auteur:
Bonnefoi, H. Jacot, W. Saghatchian, M. Moldovan, C. Venat-Bouvet, L. Zaman, K. Matos, E. Petit, T. Bodmer, A. Quenel-Tueux, N. Chakiba, C. Vuylsteke, P. Jerusalem, G. Brain, E. Tredan, O. Messina, C.G.M. Slaets, L. Cameron, D.